RAX103

RAX103 is a novel somatostatin receptor subtype 2 (SSTR2)-targeted cyclic peptide radioligand being developed as a theranostic agent for the treatment and imaging of SSTR2-expressing malignancies, including gastroenteropancreatic neuroendocrine tumors (GEP-NETs), small cell lung cancer, and breast cancer. Developed by RadAlliance Therapeutics, RAX103 is designed with non-natural amino acids to optimize SSTR2 binding affinity and significantly reduce renal retention compared to standard-of-care agents like dotatate. By achieving a substantially higher tumor-to-kidney ratio, RAX103 aims to mitigate dose-limiting nephrotoxicity and potentially eliminate the need for intensive amino-acid infusion protocols during peptide receptor radionuclide therapy (PRRT). It is being evaluated in preclinical studies and early-stage clinical translation with both beta-emitting (lutetium-177) and alpha-emitting (actinium-225) radionuclides.

Other names

177Lu-RAX103225Ac-RAX103